Literature DB >> 29948477

Comprehensive Registry of Esophageal Cancer in Japan, 2011.

Yuji Tachimori1, Soji Ozawa2, Hodaka Numasaki3, Ryu Ishihara4, Hisahiro Matsubara5, Kei Muro6, Tsuneo Oyama7, Yasushi Toh8, Harushi Udagawa9, Takashi Uno10.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 29948477      PMCID: PMC6021481          DOI: 10.1007/s10388-018-0614-z

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


× No keyword cloud information.

Preface 2011

We deeply appreciate the great contributions of many physicians in the registry of esophageal cancer cases. The Comprehensive Registry of Esophageal Cancer in Japan, 2011, was published here, despite some delay. The registry complies with the Act for the Protection of Personal Information. The encryption with an HASH function is used for anonymity in an unlinkable fashion. We briefly summarized the Comprehensive Registry of Esophageal Cancer in Japan, 2011. Japanese Classification of Esophageal Cancer 10th and UICC TNM Classification 7th were used for cancer staging according to the subjected year. A total of 6993 cases were registered from 300 institutions in Japan. Tumor locations were cervical: 4.5%, upper thoracic: 13.0%, middle thoracic: 47.8%, lower thoracic: 27.2%, and EG junction: 7.1%. Superficial carcinomas (Tis, T1a, and T1b) were 36.4%. For the histologic type of biopsy specimens, squamous cell carcinoma and adenocarcinoma accounted for 88.3 and 5.3%, respectively. Regarding clinical results, the 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, or esophagectomy were 86.0, 28.1, 26.5, and 54.5%, respectively. The endoscopic submucosal dissection accounted for 78.1% of endoscopic resection. Esophagectomy was performed in 4147 cases. Concerning the approach used for esophagectomy, 33.5% of the cases were treated thoracoscopically. The operative mortality (within 30 days after surgery) was 0.65% and the hospital mortality was 3.76%. The 5-year survival rate of patients with pStage IV in UICC classification (including patients with supraclavicular node metastasis) was better than that of patients with pStage IVb in JES classification (not including patients with supraclavicular node metastasis). We hope that this Comprehensive Registry of Esophageal Cancer in Japan for 2011 will help to improve all aspects of the diagnosis and treatment of esophageal cancer in Japan.

Contents

Clinical factors of esophageal cancer patients treated in 2011 Institution-registered cases in 2011 Patient background Table Age and gender
Table 1

Age and gender

AgeMaleFemaleCases (%)
≤ 29415 (0.1%)
30 – 3922830 (0.4%)
40 – 4914247189 (2.7%)
50 – 598781731051 (15.0%)
60 – 6925313602891 (41.3%)
70 – 7919413332274 (32.5%)
80 – 8944290532 (7.6%)
90–13821 (0.3%)
Total597310206993
Table Primary treatment
Table 2

Primary treatment

TreatmentsCases (%)
Surgery4236 (60.7%)
 Esophagectomy4147 (59.4%)
 Palliative surgery89 (1.3%)
Chemotherapy/radiotherapy1549 (22.2%)
Endoscopic treatment1198 (17.2%)
Total6983
Table Tumor location
Table 3

Tumor location

Location of tumorEndoscopic treatment (%)SurgeryChemotherapy and/or radiotherapy (%)Total (%)
Esophagectomy (%)Palliative surgery (%)
Cervical33 (2.8%)127 (3.1%)4 (4.5%)147 (9.5%)311 (4.5%)
Upper thoracic116 (9.7%)517 (12.5%)18 (20.2%)256 (16.5%)907 (13.0%)
Middle thoracic687 (57.3%)1873 (45.2%)46 (51.7%)732 (47.3%)3338 (47.8%)
Lower thoracic296 (24.7%)1235 (29.8%)20 (22.5%)345 (22.3%)1896 (27.2%)
EG41 (3.4%)300 (7.2%)036 (2.3%)377 (5.4%)
E = G9 (0.8%)47 (1.1%)01 (0.1%)57 (0.8%)
GE5 (0.4%)40 (1.0%)1 (1.1%)2 (0.1%)48 (0.7%)
Unknown11 (0.9%)8 (0.2%)030 (1.9%)49 (0.7%)
Total119841478915496983

E esophageal, G gastric

Table Histologic types of biopsy specimens
Table 4

Histologic types of biopsy specimens

Histologic typesCases (%)
Squamous cell carcinoma6164 (88.3%)
 Squamous cell carcinoma4369 (62.6%)
 Well differentiated378 (5.4%)
 Moderately differentiated1054 (15.1%)
 Poorly differentiated363 (5.2%)
Adenocarcinoma281 (4.0%)
Barrett’s adenocarcinoma90 (1.3%)
Adenosquamous carcinoma15 (0.2%)
Mucoepidermoid carcinoma4 (0.1%)
Basaloid carcinoma35 (0.5%)
Neuroendocrine cell tumor26 (0.4%)
Undifferentiated carcinoma8 (0.1%)
Sarcoma6 (0.1%)
Malignant melanoma19 (0.3%)
Carcinosarcoma22 (0.3%)
GIST7 (0.1%)
Other tumors92 (1.3%)
Unknown214 (3.1%)
Total6983
Table Depth of tumor invasion, cT (UICC TNM 7th)
Table 5

Depth of tumor invasion, cT (UICC TNM 7th)

cTCases (%)
cTX71 (1.0%)
cT010 (0.1%)
cTis198 (2.8%)
cT1a1051 (15.1%)
cT1b1292 (18.5%)
cT2905 (13.0%)
cT32408 (34.5%)
cT4a384 (5.5%)
cT4b530 (7.6%)
Unknown134 (1.9%)
Total6983
Table Lymph node metastasis, cN (UICC TNM 7th)
Table 6

Lymph node metastasis, cN (UICC TNM 7th)

cNCases (%)
cNX187 (2.7%)
cN03195 (45.8%)
cN11864 (26.7%)
cN21199 (17.2%)
cN3459 (6.6%)
Unknown79 (1.1%)
Total6983
Table Distant metastasis, cM (UICC TNM 7th)
Table 7

Distant metastasis, cM (UICC TNM 7th)

cMCases (%)
cM06128 (87.8%)
cM1722 (10.3%)
Unknown133 (1.9%)
Total6983
Table Clinical stage (UICC TNM 7th)
Table 8

Clinical stage (UICC TNM 7th)

Clinical stageEndoscopic treatment (%)SurgeryChemotherapy and/or radiotherapy (%)Total (%)
Esophagectomy (%)Palliative surgery (%)
Stage 0151 (12.6%)15 (0.4%)07 (0.5%)173 (2.5%)
Stage IA809 (67.5%)937 (22.6%)1 (1.1%)161 (10.4%)1908 (27.3%)
Stage IB2 (0.2%)363 (8.8%)1 (1.1%)58 (3.7%)424 (6.1%)
Stage IIA3 (0.3%)419 (10.1%)3 (3.4%)60 (3.9%)485 (6.9%)
Stage IIB4 (0.3%)470 (11.3%)1 (1.1%)63 (4.1%)538 (7.7%)
Stage IIIA10 (0.8%)898 (21.7%)14 (15.7%)147 (9.5%)1069 (15.3%)
Stage IIIB6 (0.5%)456 (11.0%)9 (10.1%)99 (6.4%)570 (8.2%)
Stage IIIC32 (2.7%)292 (7.0%)27 (30.3%)390 (25.2%)741 (10.6%)
Stage IV40 (3.3%)165 (4.0%)25 (28.1%)434 (28.0%)664 (9.5%)
Unknown141 (11.8%)132 (3.2%)8 (9.0%)130 (8.4%)411 (5.9%)
Total119841478915496983
Results of endoscopically treated patients in 2011 Table Details of endoscopic treatment for curative intent
Table 9

Details of endoscopic treatment for curative intent

Treatment detailsCases (%)
EMR190 (17.9%)
EMR + YAG laser13 (1.2%)
ESD829 (78.1%)
ESD + EMR5 (0.5%)
ESD + PDT0
ESD + YAG laser5 (0.5%)
PDT2 (0.2%)
YAG laser18 (1.7%)
Total1062

EMR endoscopic mucosal resection, ESD endoscopic submucosal dissection, YAG yttrium aluminum garnet, PDT photodynamic therapy

Table Complications of EMR/ESD
Table 10

Complications of EMR/ESD

Complications of EMR/ESDCases (%)
None969 (93.0%)
Perforation13 (1.2%)
Bleeding3 (0.3%)
Mediastinitis3 (0.3%)
Stenosis49 (4.7%)
Others4 (0.4%)
Total1042
Table Pathological depth of tumor invasion of EMR/ESD specimens
Table 11

Pathological depth of tumor invasion of EMR/ESD specimens

Pathological depth of tumor invasion (pT)Cases (%)
pTX3 (0.3%)
pT07 (0.7%)
pTis201 (19.3%)
pT1a703 (67.5%)
pT1b114 (10.9%)
pT23 (0.3%)
Unknown11 (1.1%)
Total1042
Figure Survival of patients treated with EMR/ESD
Fig. 1

Survival of patients treated with EMR/ESD

Figure Survival of patients treated with EMR/ESD according to the pathological depth of tumor invasion (pT)
Fig. 2

Survival of patients treated with EMR/ESD according to the pathological depth of tumor invasion (pT)

Figure Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion
Fig. 3

Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion

Results in patients treated with chemotherapy and/or radiotherapy in 2011 Table Dose of irradiation (non-surgically treated cases)
Table 12

Dose of irradiation (non-surgically treated cases)

Dose of irradiation (Gy)DefinitivePalliative (%)Recurrence (%)Others (%)Unknown (%)Total (%)
Radiation alone (%)Chemoradiotherapy (%)
− 296 (3.5%)13 (1.7%)32 (10.9%)02 (5.7%)053 (4.1%)
30–394 (2.3%)17 (2.2%)40 (13.6%)02 (5.7%)063 (4.9%)
40–498 (4.6%)33 (4.2%)34 (11.6%)010 (28.6%)085 (6.6%)
50–5929 (16.8%)177 (22.7%)71 (24.1%)1 (25.0%)11 (31.4%)1 (50.0%)290 (22.5%)
60–69116 (67.1%)516 (66.1%)108 (36.7%)3 (75.0%)9 (25.7%)0752 (58.3%)
70–9 (5.2%)12 (1.5%)3 (1.0%)01 (2.9%)025 (2.2%)
Unknown1 (0.6%)13 (1.7%)6 (2.0%)001 (50.0%)21 (1.6%)
Total17378129443521289
Median (min–max)60.0 (4.4–70.0)60.0 (1.8–120.0)50.4 (3.6–159.0)60.0 (50.0–61.2)50.0 (21.6–109.0)54.0 (54.0–54.0)60.0 (1.8–105.0)
Table Dose of irradiation (surgically treated cases)
Table 13

Dose of irradiation (surgically treated cases)

Dose of irradiation (Gy)Preoperative irradiation (%)Postoperative irradiation (%)
–295 (2.2%)3 (6.0%)
30–3939 (17.1%)0
40–49156 (68.4%)8 (16.0%)
50–5915 (6.6%)15 (30.0%)
60–696 (2.6%)15 (30.0%)
70–1 (0.4%)0
Unknown6 (2.6%)9 (18.0%)
Total22850
Median (min–max)40.0 (1.8–70.0)50.4 (2.0–66.0)
Figure Survival of patients treated with chemotherapy and/or radiotherapy
Fig. 4

Survival of patients treated with chemotherapy and/or radiotherapy

Figure Survival of patients treated with definitive chemoradiotherapy according to clinical stage (UICC TNM 7th)
Fig. 5

Survival of patients treated with definitive chemoradiotherapy according to clinical stage (UICC TNM 7th)

Figure Survival of patients underwent radiotherapy alone according to clinical stage (UICC TNM 7th)
Fig. 6

Survival of patients underwent radiotherapy alone according to clinical stage (UICC TNM 7th)

Results in patients who underwent esophagectomy in 2011 Table Treatment modalities of esophagectomy
Table 14

Treatment modalities of esophagectomy

TreatmentsCases (%)
Esophagectomy alone1699 (41.2%)
Esophagectomy + endoscopic treatment89 (2.2%)
Esophagectomy + chemoradiotherapy590 (14.3%)
 Concurrent chemoradiotherapy370 (9.0%)
 Other220 (5.3%)
Esophagectomy + chemoradiotherapy + endoscopic treatment21 (0.5%)
Esophagectomy + chemotherapy1657 (40.2%)
 Preoperative1295 (31.4%)
 Postoperative198 (4.8%)
 Preoperative and postoperative57 (1.4%)
 Recurrence107 (2.6%)
 Other20 (0.5%)
Esophagectomy + chemotherapy + endoscopic treatment1 (0.0%)
Esophagectomy + radiotherapy67 (1.6%)
 Preoperative17 (0.4%)
 Postoperative13 (0.3%)
 Recurrence5 (0.1%)
 Other32 (0.8%)
Esophagectomy + radiotherapy + endoscopic treatment3 (0.1%)
Total4127
Table Tumor location
Table 15

Tumor location

LocationsCases (%)
Cervical127 (3.1%)
Upper thoracic517 (12.5%)
Middle thoracic1873 (45.2%)
Lower thoracic1235 (29.8%)
E > G300 (7.2%)
E = G47 (1.1%)
G > E40 (1.0%)
Unknown8 (0.2%)
Total lesions4147
Table Approaches to tumor resection
Table 16

Approaches to tumor resection

ApproachesCases (%)
Cervical approach96 (2.3%)
Right thoracic3459 (83.4%)
Left thoracic67 (1.6%)
Left thoracoabdominal72 (1.7%)
Abdominal172 (4.1%)
Transhiatal thoracic esophagectomy51 (1.2%)
Transhiatal lower esophagectomy82 (2.0%)
Sternotomy9 (0.2%)
Others33 (0.8%)
Unknown106 (2.6%)
Total4147

Thoracic includes thoracotomy and thoracoscopic. Abdominal includes laparotomy and laparoscopic

Table Video-assisted surgery
Table 17

Video-assisted surgery

Video-assisted surgeryCases (%)
None2389 (57.6%)
Thoracoscopy768 (18.5%)
Thoracoscopy + Laparoscopy605 (14.6%)
Thoracoscopy + Laparoscopy + Mediastinoscopy15 (0.4%)
Thoracoscopy + Mediastinoscopy2 (0.0%)
Laparoscopy201 (4.8%)
Laparoscopy + Mediastinoscopy14 (0.3%)
Laparoscopy + Other2 (0.0%)
Mediastinoscopy21 (0.5%)
Others4 (0.1%)
Total4147
Table Fields of lymph node dissection according to the location of the tumor
Table 18

Fields of lymph node dissection according to the location of the tumor

Field of lymphadenectomyCervicalUpper thoracicMiddle thoracicLower thoracicE > GE = GG > EUnknownTotal
None10 (8.6%)13 (3.2%)59 (3.5%)28 (2.7%)13 (5.4%)2 (25.0%)125 (3.5%)
C36 (31.0%)10 (2.4%)20 (1.2%)3 (0.3%)1 (0.4%)70 (2.0%)
C + UM21 (18.1%)6 (1.5%)3 (0.2%)1 (0.1%)31 (0.9%)
C + UM + MLM2 (1.7%)12 (2.9%)28 (1.7%)12 (1.1%)1 (3.7%)55 (1.5%)
C + UM + MLM + A27 (23.3%)257 (62.5%)800 (47.9%)367 (34.8%)26 (10.8%)6 (15.8%)1 (12.5%)1484 (41.6%)
C + UM + MLM + A+OT1 (0.1%)1 (0.0%)
C + UM + A2 (1.7%)1 (0.2%)2 (0.1%)2 (0.2%)7 (0.2%)
C + MLM1 (0.1%)1 (0.0%)
C + MLM + A3 (2.6%)1 (0.2%)7 (0.4%)3 (0.3%)14 (0.4%)
C + A1 (0.9%)2 (0.5%)4 (0.2%)2 (0.2%)1 (0.4%)10 (0.3%)
UM4 (3.4%)3 (0.7%)5 (0.3%)3 (0.3%)15 (0.4%)
UM + MLM1 (0.9%)7 (1.7%)29 (1.7%)12 (1.1%)1 (0.4%)1 (12.5%)51 (1.4%)
UM + MLM + A3 (2.6%)75 (18.2%)627 (37.6%)478 (45.4%)56 (23.2%)5 (13.2%)1 (3.7%)1 (12.5%)1246 (35.0%)
UM + A1 (0.9%)4 (1.0%)2 (0.1%)2 (0.2%)2 (0.8%)11 (0.3%)
MLM3 (0.7%)10 (0.6%)14 (1.3%)3 (1.2%)30 (0.8%)
MLM + A1 (0.9%)7 (1.7%)34 (2.0%)102 (9.7%)108 (44.8%)23 (60.5%)17 (63.0%)292 (8.2%)
A1 (0.9%)6 (1.5%)22 (1.3%)12 (1.1%)28 (11.6%)3 (7.9%)8 (29.6%)1 (12.5%)81 (2.3%)
Unknown3 (2.6%)4 (1.0%)16 (1.0%)12 (1.1%)2 (0.8%)1 (2.6%)2 (25.0%)40 (1.1%)
Total11641116691054241382783564

C bilateral cervical nodes, UM upper mediastinal nodes, MLM middle–lower mediastinal nodes, A abdominal nodes

Table Reconstruction route
Table 19

Reconstruction route

Reconstruction routeCases (%)
None56 (1.4%)
Subcutaneous384 (9.3%)
Retrosternal1437 (34.7%)
Posterior mediastinal1715 (41.4%)
Intrathoracic419 (10.1%)
Cervical35 (0.8%)
Others34 (0.8%)
Unknown67 (1.6%)
Total4147
Table Organs used for reconstruction
Table 20

Organs used for reconstruction

Organs used for reconstructionCases (%)
None76 (1.8%)
Whole stomach63 (1.5%)
Gastric tube3508 (83.6%)
Jejunum255 (6.1%)
Free jejunum76 (1.8%)
Colon127 (3.0%)
Free colon13 (0.3%)
Skin graft1
Others14 (0.3%)
Unknown63 (1.5%)
Total organs4196
Total cases4147
Table Histological classification
Table 21

Histological classification

Histological classificationCases (%)
Squamous cell carcinoma3502 (84.4%)
 Squamous cell carcinoma732 (17.7%)
 Well differentiated645 (15.6%)
 Moderately differentiated1630 (39.3%)
 Poorly differentiated495 (11.9%)
Adenocarcinoma210 (5.1%)
Barrett’s adenocarcinoma78 (1.9%)
Adenosquamous carcinoma31 (0.7%)
Mucoepidermoid carcinoma3 (0.1%)
Adenoid cystic carcinoma2 (0.0%)
Basaloid carcinoma81 (2.0%)
Neuroendocrine cell tumor15 (0.4%)
Undifferentiated carcinoma8 (0.2%)
Other carcinoma9 (0.2%)
Carcinosarcoma29 (0.7%)
Malignant melanoma16 (0.4%)
GIST6 (0.1%)
Other39 (0.9%)
Unknown118 (2.8%)
Total4147
Table Depth of tumor invasion, pT (JES 10th)
Table 22

Depth of tumor invasion, pT (JES 10th)

pT categoryCases (%)
pTX57 (1.4%)
pT0128 (3.1%)
pTis31 (0.7%)
pT1a435 (10.5%)
pT1b1070 (25.8%)
pT2516 (12.4%)
pT31576 (38.0%)
pT424 (0.6%)
pT4a93 (2.2%)
pT4b89 (2.1%)
Unknown128 (3.1%)
Total4147
Table Pathological grading of lymph node metastasis, pN (JES 10th)
Table 23

Pathological grading of lymph node metastasis, pN (JES 10th)

Lymph node metastasisCases (%)
pN01970 (47.5%)
pN1616 (14.9%)
pN2949 (22.9%)
pN3323 (7.8%)
pN4209 (5.0%)
Unknown80 (1.9%)
Total4147
Table Pathological findings of lymph node metastasis, pN (UICC 7th)
Table 24

Pathological findings of lymph node metastasis, pN (UICC 7th)

Lymph node metastasisCases (%)
pN01871 (45.1%)
pN1 (1–2)1165 (28.1%)
pN2 (3–6)659 (15.9%)
pN3 (7–)366 (8.8%)
Unknown86 (2.1%)
Total4147

Regional lymph nodes are different in JES 10th and UICC 7th

Data for Tables 23 and 24 were analyzed from different variables in the registration application

Table Pathological findings of distant organ metastasis, pM (JES 10th)
Table 25

Pathological findings of distant organ metastasis, pM (JES 10th)

Distant metastasisCases (%)
pMX195 (4.7%)
pM03886 (93.7%)
pM166 (1.6%)
Total4147
Table Residual tumor
Table 26

Residual tumor

Residual tumorCases (%)
RX147 (3.5%)
R03624 (87.4%)
R1219 (5.3%)
R2157 (3.8%)
Total4147
Table Causes of death
Table 27

Causes of death

Cause of deathCases (%)
Death due to recurrence1223 (71.2%)
Death due to other cancer71 (4.1%)
Death due to other disease (rec+)42 (2.4%)
Death due to other disease (rec−)239 (13.9%)
Death due to other disease (rec?)9 (0.5%)
Operative death*27 (1.6%)
Postoperative hospital death**55 (3.2%)
Unknown51 (3.0%)
Total of death cases1717

rec: recurrence

*Operative death means death within 30 days after operation in or out of hospital

**Hospital death is defined as death during the same hospitalization, regardless of department at time of death

Operative mortality after esophagectomy: 0.65%

Hospital mortality after esophagectomy: 3.76%

Figure Survival of patients who underwent esophagectomy
Fig. 7

Survival of patients who underwent esophagectomy

Figure Survival of patients who underwent esophagectomy according to clinical stage (JES 10th)
Fig. 8

Survival of patients who underwent esophagectomy according to clinical stage (JES 10th)

Figure Survival of patients who underwent esophagectomy according to clinical stage (UICC 7th)
Fig. 9

Survival of patients who underwent esophagectomy according to clinical stage (UICC 7th)

Figure Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th)
Fig. 10

Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th)

Figure Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (JES 10th)
Fig. 11

Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (JES 10th)

Figure Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (UICC 7th)
Fig. 12

Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (UICC 7th)

Figure Survival of patients who underwent esophagectomy according to pathological stage (JES 10th)
Fig. 13

Survival of patients who underwent esophagectomy according to pathological stage (JES 10th)

Figure Survival of patients who underwent esophagectomy according to pathological stage (UICC TNM 7th)
Fig. 14

Survival of patients who underwent esophagectomy according to pathological stage (UICC TNM 7th)

Figure Survival of patients who underwent esophagectomy according to residual tumor (R)
Fig. 15

Survival of patients who underwent esophagectomy according to residual tumor (R)

I. Clinical factors of esophageal cancer patients treated in 2011

Institution-registered cases in 2011

(Total 300 institutions)

Patient background

Age and gender Primary treatment Tumor location E esophageal, G gastric Histologic types of biopsy specimens Depth of tumor invasion, cT (UICC TNM 7th) Lymph node metastasis, cN (UICC TNM 7th) Distant metastasis, cM (UICC TNM 7th) Clinical stage (UICC TNM 7th)

II. Results of endoscopically treated patients in 2011

Details of endoscopic treatment for curative intent EMR endoscopic mucosal resection, ESD endoscopic submucosal dissection, YAG yttrium aluminum garnet, PDT photodynamic therapy Complications of EMR/ESD Pathological depth of tumor invasion of EMR/ESD specimens Survival of patients treated with EMR/ESD Survival of patients treated with EMR/ESD according to the pathological depth of tumor invasion (pT) Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion

III. Results in patients treated with chemotherapy and/or radiotherapy in 2011

Dose of irradiation (non-surgically treated cases) Dose of irradiation (surgically treated cases) Survival of patients treated with chemotherapy and/or radiotherapy Survival of patients treated with definitive chemoradiotherapy according to clinical stage (UICC TNM 7th) Survival of patients underwent radiotherapy alone according to clinical stage (UICC TNM 7th)

IV. Results in patients who underwent esophagectomy in 2011

Treatment modalities of esophagectomy Tumor location Approaches to tumor resection Thoracic includes thoracotomy and thoracoscopic. Abdominal includes laparotomy and laparoscopic Video-assisted surgery Fields of lymph node dissection according to the location of the tumor C bilateral cervical nodes, UM upper mediastinal nodes, MLM middle–lower mediastinal nodes, A abdominal nodes Reconstruction route Organs used for reconstruction Histological classification Depth of tumor invasion, pT (JES 10th) Pathological grading of lymph node metastasis, pN (JES 10th) Pathological findings of lymph node metastasis, pN (UICC 7th) Regional lymph nodes are different in JES 10th and UICC 7th Data for Tables 23 and 24 were analyzed from different variables in the registration application Pathological findings of distant organ metastasis, pM (JES 10th) Residual tumor Causes of death rec: recurrence *Operative death means death within 30 days after operation in or out of hospital **Hospital death is defined as death during the same hospitalization, regardless of department at time of death Operative mortality after esophagectomy: 0.65% Hospital mortality after esophagectomy: 3.76% Survival of patients who underwent esophagectomy Survival of patients who underwent esophagectomy according to clinical stage (JES 10th) Survival of patients who underwent esophagectomy according to clinical stage (UICC 7th) Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th) Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (JES 10th) Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (UICC 7th) Survival of patients who underwent esophagectomy according to pathological stage (JES 10th) Survival of patients who underwent esophagectomy according to pathological stage (UICC TNM 7th) Survival of patients who underwent esophagectomy according to residual tumor (R)
Institution
Ageo Central General Hospital
Aichi Cancer Center
Aichi Medical University Hospital
Aizawa Hospital
Akita Kouseiren Hiraga Hospital
Akita University Hospital
Arao Municipal Hospital
Asahikawa Medical College Hospital
Asahikawa-Kosei General Hospital
Chiba Cancer Center
Chiba Medical Center
Chiba Prefectural Sawara Hospital
Chiba University Hospital
Chigasaki Municipal Hospital
Dokkyo Medical University Hospital
Dokkyo Medical University Saitama Medical Center
Eiju General Hospital
Foundation for Detection of Early Gastric Carcinoma
Fuchu Hospital
Fujioka General Hospital
Fujisawa Shounandai Hospital
Fujita Health University
Fukui Prefectural Hospital
Fukui University Hospital
Fukui-ken Saiseikai Hospital
Fukuoka Dental College and Dental Hospital
Fukuoka Saiseikai General Hospital
Fukuoka University Chikushi Hospital
Fukuoka University Hospital
Fukuoka Wajiro Hospital
Fukushima Medical University Hospital
Fukuyama City Hospital
Fussa Hospital
Gifu Prefectural General Medical Center
Gifu University Hospital
Gunma Central General Hospital
Gunma Prefectural Cancer Center
Gunma University Hospital
Gunmaken Saiseikai Maebashi Hospital
Hachinohe City Hospital
Hakodate Goryokaku Hospital
Hakodate National Hospital
Hamamatsu University School of Medicine, University Hospital
Hannan Chuo Hospital
Heartlife Hospital
Higashiosaka City Medical Center
Hino Memorial Hospital
Hino Municipal Hospital
Hiratsuka City Hospital
Hiratsuka Kyosai Hospital
Hirosaki University Hospital
Hiroshima City Asa Hospital
Hiroshima City Hiroshima Citizens Hospital
Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital
Hiroshima University Hospital
Hitachi General Hospital
Hofu Institute of Gastroenterology
Hokkaido University Hospital
Hyogo Cancer Center
Hyogo College of Medicine
Hyogo Prefectural Nishinomiya Hospital
Ibaraki Prefectural Central Hospital
Iizuka Hospital
Imazu Surgical Clinic
Inazawa City Hospital
International University of Health and Welfare Hospital
International Goodwill Hospital
Isehara Kyodo Hospital
Ishikawa Prefectural Central Hospital
Iwakuni Medical Center
Iwate Medical University Hospital
Iwate Prefectural Chubu Hospital
Iwate Prefectural Isawa Hospital
Japanese Red Cross Fukui Hospital
Japanese Red Cross Ishinomaki Hospital
Japanese Red Cross Kyoto Daini Hospital
Japanese Red Cross Nagaoka Hospital
Japanese Red Cross Okayama Hospital
JCHO Kyushu Hospital
JCHO Osaka Hospital
Jichi Medical University Hospital
Jichi Medical University Saitama Medical Center
Juntendo University Hospital
Juntendo University Shizuoka Hospital
Kagawa Prefectural Central Hospital
Kagawa Rosai Hospital
Kagawa University Hospital
Kagoshima Kenritsu Satsunan Hospital
Kagoshima University Hospital
Kameda General Hospital
Kanagawa Cancer Center
Kanazawa Medical University Hospital
Kanazawa University Hospital
Kansai Medical University Hospital
Kansai Rosai Hospital
Kasamatsu Hospital
Kashiwa Kousei General Hospital
Kawasaki Medical School Hospital
Kawasaki Medical School Kawasaki Hospital
Kawasaki Municipal Ida Hospital
Nara Hospital Kinki University Faculty of Medicine
Nara Medical University Hospital
National Cancer Center Hospital
National Cancer Center Hospital East
National Center for Global Health and Medicine
National Defense Medical College Hospital
National Hospital Organization Beppu Medical Center
National Hospital Organization Chiba Medical Center
National Hospital Organization Chiba-East-Hospital
National Hospital Organization Fukuoka-higashi Medical Center
National Hospital Organization Hokkaido Cancer Center
National Hospital Organization Iwakuni Medical Center
National Hospital Organization Kanmon Medical Center
National Hospital Organization Kure Medical Center
National Hospital Organization Kyoto Medical Center
National Hospital Organization Kyushu Cancer Center
National Hospital Organization Matsumoto Medical Center
National Hospital Organization Nagasaki Medical Center
National Hospital Organization Nagoya Medical Center
National Hospital Organization Okayama Medical Center
National Hospital Organization Osaka National Hospital
National Hospital Organization Tokyo Medical Center
Niigata Cancer Center Hospital
Niigata City General Hospital
Niigata Prefectural Shibata Hospital
Niigata University Medical and Dental Hospital
Nikko Memorial Hospital
Nippon Medical School Chiba Hokusoh Hospital
Nippon Medical School Hospital
Nippon Medical School Musashi Kosugi Hospital
Nippon Medical School Tama Nagayama Hospital
Nishi-Kobe Medical Center
Nishinomiya Municipal Central Hospital
NTT WEST Osaka Hospital
Numazu City Hospital
Obihiro Kousei General Hospital
Ogaki Municipal Hospital
Ohta General Hospital Foundation Ohta Nishinouchi Hospital
Oita Red Cross Hospital
Oita University Hospital
Okayama Saiseikai General Hospital
Okayama University Hospital
Osaka City University Hospital
Osaka Hospital of Japan Seafarers relief Association
Osaka International Cancer Institute
Osaka Medical College Hospital
Osaka Police Hospital
Osaka Prefectural Hospital Organization Osaka General Medical Center
Osaka Red Cross Hospital
Osaka University Hospital
Otsu City Hospital
Otsu Red Cross Hospital
Rinku General Medical Center
Ryukyu University Hospital
Saga University Hospital
Saga-ken Medical Center Koseikan
Saiseikai Fukushima General Hospital
Saiseikai Kyoto Hospital
Saiseikai Utsunomiya Hospital
Saiseikai Yahata General Hospital
Saitama Cancer Center
Saitama City Hospital
Saitama Medical Center
Saitama Medical University Hospital
Saitama Medical University Saitama Medical Center
Sakai City Medical Center
Saku Central Hospital
Sanin Rosai Hospital
Sano Kousei General Hospital
Sato Clinic
Sendai City Hospital
Sendai Medical Center
Shiga University of Medical Science Hospital
Shikoku Cancer Center
Shimane University Hospital
Shimizu Welfare Hospital
Shin Beppu Hospital
Shinko Hospital
Shizuoka Cancer Center
Shizuoka City Shizuoka Hospital
Shizuoka General Hospital
Showa University Fujigaoka Hospital
Showa University Hospital
Showa University Koto-Toyosu Hospital
Social Insurance Omuta Tenryo Hospital
Social Insurance Tagawa Hospital
St. Marianna University School of Medical Hospital
St. Luke’s International Hospital
Sugita Genpaku Memorial Obama Municipal Hospital
Suita Municipal Hospital
Takasago Municipal Hospital
Teikyo University Chiba Medical Center
Teikyo University Hospital
Tenri Hospital
The Cancer Institute Hospital of JFCR
The Jikei University Daisan Hospital
The Jikei University Hospital
The Research Center Hospital for Charged Particle Therapy of NIRS
Tochigi Cancer Center
Toho University Ohashi Medical Center
Toho University Omori Medical Center
Toho University Sakura Medical Center
Tohoku Kosai Hospital
Tohoku University Hospital
Tokai University Hachioji Hospital
Tokai University Hospital
Tokai University Tokyo Hospital
Tokushima Red Cross Hospital
Tokushima University Hospital
Tokuyama Central Hospital
Tokyo Dental College Ichikawa General Hospital
Tokyo Medical and Dental University Hospital
Tokyo Medical University Hospital
Tokyo Medical University Ibaraki Medical Center
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Tokyo Metropolitan Health and Medical Corporation Toshima Hospital
Tokyo Metropolitan Tama Medical Center
Tokyo Saiseikai Central Hospital
Tokyo University Hospital
Tokyo Women’s Medical University Hospital
Tokyo Women’s Medical University Medical Center East
Tokyo Women’s Medical University Yachiyo Medical Center
Tonan Hospital
Tone Chuo Hospital
Toranomon Hospital
Tottori Prefectural Central Hospital
Tottori University Hospital
Toyama Prefectural Central Hospital
Toyama University Hospital
Toyonaka Municipal Hospital
Tsuchiura Kyodo Hospital
Tsukuba University Hospital
Tsuruoka Municipal Shonai Hospital
University Hospital, Kyoto Prefectural University of Medicine
University of Miyazaki Hospital
Urasoe General Hospital
Wakayama Medical University Hospital
Yamagata Prefectural and Sakata Municipal Hospital Organization
Yamagata Prefectural Central Hospital
Yamagata Prefectural Shinjo Hospital
Yamagata University Hospital
Yamaguchi University Hospital
Yamaguchi-ken Saiseikai Shimonoseki General Hospital
Yamanashi Prefectural Central Hospital
Yamanashi University Hospital
Yao Municipal Hospital
Yokohama Chuo Hospital
Yokohama City Municipal Hospital
Yokohama City University Medical Center
Yokohama Rosai Hospital

(Total 300 institutions)

  23 in total

1.  Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma.

Authors:  Yoko Hiraki; Yutaka Kimura; Motohiro Imano; Hiroaki Kato; Mitsuru Iwama; Osamu Shiraishi; Atsushi Yasuda; Masayuki Shinkai; Tomoki Makino; Masaaki Motoori; Makoto Yamasaki; Hiroshi Miyata; Takao Satou; Taroh Satoh; Hiroshi Furukawa; Masahiko Yano; Yuichiro Doki; Takushi Yasuda
Journal:  Surg Today       Date:  2020-06-28       Impact factor: 2.549

2.  Predictive factors of difficulty of thoracoscopic esophagectomy in the left decubitus position.

Authors:  Yushi Fujiwara; Shigeru Lee; Ken Gyobu; Daiki Inazu; Ryoko Naka; Masaki Nishiyama; Masaichi Ohira; Harushi Osugi
Journal:  Esophagus       Date:  2019-04-30       Impact factor: 4.230

3.  Molecular and clinicopathological analyses of esophageal carcinosarcoma with special reference to morphological change.

Authors:  Sho Tsuyama; Tsuyoshi Saito; Yoichi Akazawa; Yuka Yanai; Noboru Yatagai; Keisuke Akaike; Takuo Hayashi; Yoshiyuki Suehara; Fumiyuki Takahashi; Kazuya Takamochi; Takashi Hashimoto; Yoshiaki Kajiyama; Masahiko Tsurumaru; Tetsu Fukunaga; Takashi Yao
Journal:  Virchows Arch       Date:  2019-08-23       Impact factor: 4.064

4.  Current status of radiotherapy for patients with thoracic esophageal cancer in Japan, based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.

Authors:  Yasushi Toh; Hodaka Numasaki; Yuji Tachimori; Takashi Uno; Keiichi Jingu; Kenji Nemoto; Hisahiro Matsubara
Journal:  Esophagus       Date:  2019-08-31       Impact factor: 4.230

5.  The effectiveness of serum midkine in detecting esophageal squamous cell carcinoma.

Authors:  Fumiaki Shiratori; Masaaki Ito; Satoshi Yajima; Takashi Suzuki; Yoko Oshima; Tatsuki Nanami; Kimihiko Funahashi; Hideaki Shimada
Journal:  Esophagus       Date:  2019-02-18       Impact factor: 4.230

Review 6.  Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma.

Authors:  Ankur K Nagaraja; Osamu Kikuchi; Adam J Bass
Journal:  Cancer Discov       Date:  2019-11-14       Impact factor: 39.397

Review 7.  Advances in the surgical treatment of esophageal cancer since 1965.

Authors:  Hisahiro Matsubara
Journal:  Ann Gastroenterol Surg       Date:  2020-04-14

8.  Failure patterns after adjuvant chemoradiotherapy following endoscopic resection for superficial esophageal squamous cell carcinoma.

Authors:  Toshiki Ikawa; Ryu Ishihara; Koji Konishi; Masahiro Morimoto; Takero Hirata; Naoyuki Kanayama; Sachiko Yamamoto; Noriko Matsuura; Kentaro Wada; Kenji Hayashi; Kazuhiko Ogawa; Teruki Teshima
Journal:  Cancer Med       Date:  2019-06-20       Impact factor: 4.452

9.  Prognostic significance of IMP-3 expression pattern in esophageal squamous cell carcinoma.

Authors:  Terue Sakakibara; Soji Ozawa; Junya Oguma; Minoru Nakui; Soichiro Yamamoto; Hiroyasu Makuuchi; Hiroshi Kajiwara; Naoya Nakamura
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

10.  Effectiveness of salvage radiotherapy for superficial esophageal Cancer after non-curative endoscopic resection.

Authors:  Ikuno Nishibuchi; Yuji Murakami; Yoshinori Adachi; Nobuki Imano; Yuki Takeuchi; Ippei Tkahashi; Tomoki Kimura; Yuji Urabe; Shiro Oka; Shinji Tanaka; Yasushi Nagata
Journal:  Radiat Oncol       Date:  2020-06-01       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.